117 related articles for article (PubMed ID: 37759243)
1. Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
Arafa MA; Farhat KH; Khan FK; Rabah DM; Elmorshedy H; Mokhtar A; Al-Taweel W
Prostate; 2024 Jan; 84(1):56-63. PubMed ID: 37759243
[TBL] [Abstract][Full Text] [Related]
2. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
3. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
4. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
5. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
6. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis.
Ge Q; Zhang S; Xu H; Zhang J; Fan Z; Li W; Shen D; Xiao J; Wei Z
Cancer Med; 2023 Dec; 12(24):21820-21829. PubMed ID: 38014481
[TBL] [Abstract][Full Text] [Related]
8. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
9. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
[TBL] [Abstract][Full Text] [Related]
11. A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
He BM; Shi ZK; Li HS; Lin HZ; Yang QS; Lu JP; Sun YH; Wang HF
Ann Surg Oncol; 2020 Apr; 27(4):1284-1295. PubMed ID: 31848822
[TBL] [Abstract][Full Text] [Related]
12. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
13. Development and External Validation of a Prediction Model to Identify Candidates for Prostate Biopsy.
Wagaskar VG; Lantz A; Sobotka S; Ratnani P; Parekh S; Falagario UG; Li L; Lewis S; Haines Iii K; Punnen S; Wiklund P; Tewari A
Urol J; 2022 Nov; 19(5):379-385. PubMed ID: 34978065
[TBL] [Abstract][Full Text] [Related]
14. A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
Chen Z; Zhang J; Jin D; Wei X; Qiu F; Wang X; Zhao X; Pu J; Hou J; Huang Y; Huang C
BMC Cancer; 2023 Nov; 23(1):1138. PubMed ID: 37996859
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
Lee A; Lim J; Gao X; Liu L; Chia SJ
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
[TBL] [Abstract][Full Text] [Related]
16. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
[TBL] [Abstract][Full Text] [Related]
17. Performing Precise Biopsy in Naive Patients With Equivocal PI-RADS, Version 2, Score 3, Lesions: An MRI-based Nomogram to Avoid Unnecessary Surgical Intervention.
Zhang Y; Zeng N; Zhang FB; Rui Huang YX; Tian Y
Clin Genitourin Cancer; 2020 Oct; 18(5):367-377. PubMed ID: 32771334
[TBL] [Abstract][Full Text] [Related]
18. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
[No Abstract] [Full Text] [Related]
19. A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.
Xie W; Xu Z; Qiu Y; Ye W; Zhang Z; Wang C; Zang J
Biomed Res Int; 2023; 2023():9936087. PubMed ID: 36685670
[TBL] [Abstract][Full Text] [Related]
20. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]